CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...
Phase 1, Phase 2
San Francisco, California, United States and 85 other locations
inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Ph...
Phase 1
San Francisco, California, United States and 63 other locations
tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors...
Phase 1, Phase 2
Stanford, California, United States and 52 other locations
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor...
Phase 2, Phase 3
San Francisco, California, United States and 1053 other locations
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer...
Phase 1, Phase 2
Stanford, California, United States and 11 other locations
evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors...
Phase 1, Phase 2
San Francisco, California, United States and 231 other locations
pembrolizumab or irinotecan that can be given to patients who have cancers with specific molecular alterations called MSIhi (Microsatellite ...
Phase 1
San Francisco, California, United States and 27 other locations
in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The seco...
Phase 1, Phase 2
Santa Rosa, California, United States and 163 other locations
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab ver...
Phase 3
San Francisco, California, United States and 427 other locations
multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors...
Phase 1, Phase 2
San Francisco, California, United States and 6 other locations
Clinical trials
Research sites
Resources
Legal